Replies to post #111663 on Biotech Values

[DewDiligence]

…isn't MNTA's suit against Teva, in essence, an attempt to prevent TEVA from infringing on MNTA's ability to accurately characterize the molecule (and others) because MNTA has patented the technology to do this in a way that has not been done before? That ability to characterize would also be the primary reason that the FDA went to momenta during the contamination crisis, N'cest, pas?

Yes on both counts.